QR kód

Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study

Abstract Background The use of androgen receptor pathway inhibitors (ARPIs), such as abiraterone and enzalutamide, in combination with androgen deprivation therapy (ADT), has significantly enhanced outcomes in metastatic castration-sensitive prostate cancer (mCSPC). However, validated early prognost...

Celý popis

Uloženo v:
Hlavní autoři: Sila Oksuz, Oguzcan Kınıkoglu, Nisanur Sariyar, Mert Ozdemir, Deniz Isik, Heves Surmeli, Seval Ay, Hatice Odabas, Nedim Turan
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2026-04-01
Edice:BMC Cancer
Témata:
Androgen receptor pathway inhibitors
Kinetic ratio
PSA kinetics
On-line přístup:https://doi.org/10.1186/s12885-026-16037-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky